Is the Future Bright for Well-Known Biosimilar Blockbusters?

Humira Adalimumab Rheumatoid arthritis, Psoriatic arthritis, Crohn’s Disease, Ulcerative colitis 21.2
Keytruda Pembrolizumab Various cancers 20.9
Eliquis Apixaban Blood clots 18.3
Eylea Aflibercept Macular degeneration, Macular oedema, Diabetic retinopathy 12.7
Biktarvy Bictegravir, emtricitabine, and tenofovir alafenamide) HIV 10.3
Revlimid Ienalidomide Various lymphomas, Various myelomas 9.9
Stelara Ustekinumab Psoriasis, Arthritis, Colitis, Crohn’s Disease 9.7
Dupixent Dupilumab Dermatitis, Asthma, Chronic rhinosinusitis with nasal polyps 8.7
Imbruvica Ibrutinib Various cancers 8.3
Opdivo Nivolumab Various cancers 8.2
Figure 1: A timeline snapshot of the next 6 years, indicating the major patents of the blockbuster drugs that are due to expire during this timeframe.

Are you developing a biosimilar?